JP7297308B2 - 眼科用医薬組成物及びそれに関する使用 - Google Patents

眼科用医薬組成物及びそれに関する使用 Download PDF

Info

Publication number
JP7297308B2
JP7297308B2 JP2019508247A JP2019508247A JP7297308B2 JP 7297308 B2 JP7297308 B2 JP 7297308B2 JP 2019508247 A JP2019508247 A JP 2019508247A JP 2019508247 A JP2019508247 A JP 2019508247A JP 7297308 B2 JP7297308 B2 JP 7297308B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ophthalmic pharmaceutical
concentration
pilocarpine
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019508247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524826A5 (https=
JP2019524826A (ja
Inventor
ファインバウム クラース
サラムン フランク
パテル サッダー
Original Assignee
オラシス ファーマシューティカルズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オラシス ファーマシューティカルズ リミティド filed Critical オラシス ファーマシューティカルズ リミティド
Publication of JP2019524826A publication Critical patent/JP2019524826A/ja
Publication of JP2019524826A5 publication Critical patent/JP2019524826A5/ja
Priority to JP2023093802A priority Critical patent/JP7839560B2/ja
Application granted granted Critical
Publication of JP7297308B2 publication Critical patent/JP7297308B2/ja
Priority to JP2025139461A priority patent/JP2025168426A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
JP2019508247A 2016-08-19 2017-08-18 眼科用医薬組成物及びそれに関する使用 Active JP7297308B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023093802A JP7839560B2 (ja) 2016-08-19 2023-06-07 眼科用医薬組成物及びそれに関する使用
JP2025139461A JP2025168426A (ja) 2016-08-19 2025-08-25 眼科用医薬組成物及びそれに関する使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377154P 2016-08-19 2016-08-19
US62/377,154 2016-08-19
PCT/IB2017/001140 WO2018033792A2 (en) 2016-08-19 2017-08-18 Ophthalmic pharmaceutical compositions and uses relating thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093802A Division JP7839560B2 (ja) 2016-08-19 2023-06-07 眼科用医薬組成物及びそれに関する使用

Publications (3)

Publication Number Publication Date
JP2019524826A JP2019524826A (ja) 2019-09-05
JP2019524826A5 JP2019524826A5 (https=) 2020-10-01
JP7297308B2 true JP7297308B2 (ja) 2023-06-26

Family

ID=60935566

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019508247A Active JP7297308B2 (ja) 2016-08-19 2017-08-18 眼科用医薬組成物及びそれに関する使用
JP2023093802A Active JP7839560B2 (ja) 2016-08-19 2023-06-07 眼科用医薬組成物及びそれに関する使用
JP2025139461A Withdrawn JP2025168426A (ja) 2016-08-19 2025-08-25 眼科用医薬組成物及びそれに関する使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023093802A Active JP7839560B2 (ja) 2016-08-19 2023-06-07 眼科用医薬組成物及びそれに関する使用
JP2025139461A Withdrawn JP2025168426A (ja) 2016-08-19 2025-08-25 眼科用医薬組成物及びそれに関する使用

Country Status (13)

Country Link
US (6) US9867810B1 (https=)
EP (2) EP4190328A1 (https=)
JP (3) JP7297308B2 (https=)
KR (2) KR102472774B1 (https=)
CN (2) CN116726006A (https=)
AU (2) AU2017311636B2 (https=)
CA (1) CA3031370A1 (https=)
ES (1) ES2934790T3 (https=)
IL (2) IL297367A (https=)
MX (2) MX2019001877A (https=)
PL (1) PL3500255T3 (https=)
PT (1) PT3500255T (https=)
WO (1) WO2018033792A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
PT3500255T (pt) 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
PL3681500T3 (pl) * 2018-04-24 2022-08-01 Allergan, Inc. Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
EP3866790A4 (en) 2018-10-15 2022-08-03 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES
JP7670945B2 (ja) 2018-10-26 2025-05-01 オーパス・ジェネティクス・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
CA3138510A1 (en) * 2019-05-08 2020-11-12 Harrow Ip, Llc Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof
MX2023002946A (es) * 2020-09-11 2023-04-11 Intratus Nevada Inc Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida.
MX394625B (es) * 2020-11-12 2025-03-24 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia
US20240139166A1 (en) * 2021-02-04 2024-05-02 Sydnexis, Inc. Ophthalmic compositions for presbyopia
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
US11857538B2 (en) 2022-01-14 2024-01-02 Somerset Therapeutics, Llc Stable pilocarpine formulations with modified buffer characteristics and related methods
US20250154135A1 (en) * 2022-01-29 2025-05-15 Nanjing Gritpharma Co., Ltd. M-choline receptor agonist compound, preparation method therefor and use thereof
US12156868B2 (en) 2022-02-09 2024-12-03 Somerset Therapeutics, Llc Formulations of pilocarpine and brimonidine compounds and related methods
CN117414333A (zh) * 2023-11-30 2024-01-19 南京正科医药股份有限公司 盐酸毛果芸香碱滴眼液及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500244A (ja) 2003-06-13 2007-01-11 アルコン，インコーポレイテッド ２種のポリマーの相乗作用的組み合わせを含む眼科用組成物
JP2010513454A (ja) 2006-12-18 2010-04-30 ホルヘ・ルイス・ベィノッシ 老眼の治療における使用のための、副交感神経興奮薬及び抗炎症薬を含む眼科用組成物
JP2010528014A (ja) 2007-05-24 2010-08-19 アーシエックス セラピューティックス， インコーポレイテッド ドライアイを処置するための処方物および方法
US20140113946A1 (en) 2011-09-20 2014-04-24 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2015122853A1 (en) 2014-02-11 2015-08-20 Vid D.O.O. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2064160C (en) 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US6309630B1 (en) * 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
US5698533A (en) 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
TW389694B (en) 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
CA2248881A1 (en) 1996-03-13 1997-09-18 Annouk Rozier Ophthalmological composition of the type which undergoes liquid-gel phase transition
WO1998051281A1 (en) 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
JP2004503601A (ja) 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6605640B2 (en) 2001-01-31 2003-08-12 Gerard M. Nolan Method of treating certain eye diseases
US6540990B2 (en) 2000-09-22 2003-04-01 Gerard M. Nolan Physiological method of improving vision
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US20020160988A1 (en) 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US20040058926A1 (en) 2001-05-04 2004-03-25 Rebanta Bandyopadhyay Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US20030018382A1 (en) 2001-07-17 2003-01-23 Pflugfelder Stephen C. Process for improving vision
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20050208102A1 (en) 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
EP1654002B2 (en) * 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
EP1611879B1 (en) 2004-07-02 2009-08-12 Novagali Pharma SA Use of emulsions for intra- and periocular injection
WO2006062875A1 (en) 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
EP2070518A2 (en) * 2006-07-25 2009-06-17 Osmotica Corp. Ophthalmic solutions
EP2094291A1 (en) * 2006-12-21 2009-09-02 Novo Nordisk A/S Dimeric prolactin receptor ligands
BRPI0807065A2 (pt) 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos
WO2008130591A2 (en) 2007-04-18 2008-10-30 The Gi Company, Inc. Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2011079123A1 (en) 2009-12-23 2011-06-30 Alimera Sciences, Inc. Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
PT3500255T (pt) * 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500244A (ja) 2003-06-13 2007-01-11 アルコン，インコーポレイテッド ２種のポリマーの相乗作用的組み合わせを含む眼科用組成物
JP2010513454A (ja) 2006-12-18 2010-04-30 ホルヘ・ルイス・ベィノッシ 老眼の治療における使用のための、副交感神経興奮薬及び抗炎症薬を含む眼科用組成物
JP2010528014A (ja) 2007-05-24 2010-08-19 アーシエックス セラピューティックス， インコーポレイテッド ドライアイを処置するための処方物および方法
US20140113946A1 (en) 2011-09-20 2014-04-24 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2015122853A1 (en) 2014-02-11 2015-08-20 Vid D.O.O. Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration

Also Published As

Publication number Publication date
EP3500255A4 (en) 2020-03-25
US10639297B2 (en) 2020-05-05
CA3031370A1 (en) 2018-02-22
US20180318264A1 (en) 2018-11-08
WO2018033792A3 (en) 2018-03-29
JP2019524826A (ja) 2019-09-05
JP2023105147A (ja) 2023-07-28
WO2018033792A2 (en) 2018-02-22
MX2023003124A (es) 2023-03-22
MX2019001877A (es) 2019-09-13
US20250268867A1 (en) 2025-08-28
KR20190051973A (ko) 2019-05-15
IL264664B2 (en) 2023-03-01
IL297367A (en) 2022-12-01
US20220184039A1 (en) 2022-06-16
EP3500255B1 (en) 2022-11-30
PL3500255T3 (pl) 2023-03-13
AU2017311636B2 (en) 2023-08-10
IL264664B (en) 2022-11-01
IL264664A (https=) 2019-03-31
ES2934790T3 (es) 2023-02-27
PT3500255T (pt) 2023-01-10
KR20220162876A (ko) 2022-12-08
JP2025168426A (ja) 2025-11-07
US20200222369A1 (en) 2020-07-16
KR102588499B1 (ko) 2023-10-11
JP7839560B2 (ja) 2026-04-02
EP4190328A1 (en) 2023-06-07
KR102472774B1 (ko) 2022-11-30
RU2019107585A3 (https=) 2020-12-22
BR112019002967A2 (pt) 2019-05-14
AU2023226732A1 (en) 2023-09-28
RU2019107585A (ru) 2020-09-21
US20180207136A1 (en) 2018-07-26
US9867810B1 (en) 2018-01-16
CN116726006A (zh) 2023-09-12
US11129812B2 (en) 2021-09-28
CN109803652A (zh) 2019-05-24
AU2017311636A1 (en) 2019-02-14
EP3500255A2 (en) 2019-06-26
US11974986B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
JP7839560B2 (ja) 眼科用医薬組成物及びそれに関する使用
US20240382462A1 (en) Presbyopia treatments
RU2791371C2 (ru) Офтальмологические фармацевтические композиции и их применение
HK40094546A (en) Ophthalmic pharmaceutical compositions and uses relating thereto
US20260124178A1 (en) Presbyopia treatments
HK40002937A (en) Ophthalmic pharmaceutical compositions and uses relating thereto
HK40002937B (en) Ophthalmic pharmaceutical compositions and uses relating thereto
BR112019002967B1 (pt) Composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, implante, e, kit
HK40034331B (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
HK40034331A (en) Use of pilocarpine hydrochloride for the treatment of presbyopia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230607

R150 Certificate of patent or registration of utility model

Ref document number: 7297308

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150